INTRODUCTION {#s1}
============

Approximately 10% of breast cancers are associated with a heritable component, of which one-third are attributable to germline pathogenic variants in *BRCA1* and *BRCA2* ([@MCS004093TOHC8]). Beyond *BRCA1/2*, other breast cancer susceptibility genes include *TP53*, *PTEN*, *CDH1*, and *PALB2.* The PALB2 protein binds to BRCA2 and facilitates its nuclear localization and subsequent DNA repair function ([@MCS004093TOHC34]). Similar to *BRCA2*, *BRCA1* also has a binding partner---*BARD1*---that shares a high degree of structural and functional homology; both proteins contain a RING domain, a nuclear export signal, and two tandem BRCA1 carboxy-terminal (BRCT) domains and are involved in the homologous recombination repair pathway ([@MCS004093TOHC13]; [@MCS004093TOHC30]). Heterodimerization of BARD1--BRCA1 via the RING domain is crucial in the homologous recombination repair and transcriptional regulation functions of *BRCA1* ([@MCS004093TOHC13]). Studies in mice showed that BARD1-deficient mice displayed a similar phenotype as BRCA1-deficient mice ([@MCS004093TOHC24]). Independent of *BRCA1*, *BARD1* is involved in stabilizing p53 tumor suppressor via its ANK and BRCT domains ([@MCS004093TOHC10]; [@MCS004093TOHC14]).

Clinically, both *BARD1* and *BRCA1* germline pathogenic variants are enriched in more aggressive breast cancer phenotypes, such as triple-negative breast cancers (TNBCs), which are associated with higher rates of recurrence, progression, and mortality ([@MCS004093TOHC2]; [@MCS004093TOHC23]; [@MCS004093TOHC5]; [@MCS004093TOHC4]). On a molecular level, breast cancers occurring in individuals with *BARD1* germline pathogenic variants were found to share a similar somatic gene expression profile to those with *BRCA1* pathogenic variants; for example, a breast cancer patient with a germline *BARD1* deletion and tumor loss of heterozygosity showed a basal-like gene expression profile similar to those seen in cancers associated with *BRCA1* germline pathogenic variants ([@MCS004093TOHC1]; [@MCS004093TOHC2]; [@MCS004093TOHC28]).

Despite these similarities, the clinical significance of *BARD1* remains uncertain. Unlike *BRCA1*, *BARD1* germline pathogenic variants are found in \<1% of breast cancer patients ([@MCS004093TOHC5]). As a result, there is insufficient epidemiologic evidence on the role of *BARD1* as a breast cancer susceptibility gene. Moreover, the evidence can sometimes be controversial, further impeding our understanding of the clinical relevance of *BARD1*. For example, one of the most extensively studied *BARD1* germline variants, c.1670G\>C, was shown to be associated with a two- to fourfold increased breast cancer risk in some studies ([@MCS004093TOHC17], [@MCS004093TOHC18]; [@MCS004093TOHC6]; [@MCS004093TOHC26]) but not in others ([@MCS004093TOHC16]; [@MCS004093TOHC19]). Given that *BARD1* is a low-penetrance gene, its pathogenic variants likely increased the cancer risk in concert with other low- to moderate-penetrance gene alleles. The interaction among the various genetic risk loci might have led to the varying penetrance estimations observed in the various studies. Overall, existing epidemiologic data are scarce and inconsistent. Functional studies can help circumvent this by reclassifying germline variants---hence, increasing the number of pathogenic variants available for inclusion in epidemiologic studies ([@MCS004093TOHC29]; [@MCS004093TOHC31]).

Currently, *BARD1* pathogenic variants found in breast cancer patients are largely truncating mutations assumed to encode for nonfunctional proteins ([@MCS004093TOHC12]; [@MCS004093TOHC33]; [@MCS004093TOHC6]; [@MCS004093TOHC30]). Little is known about the functional impact of the majority of *BARD1* germline variants, many of which are missense. Most of these are classified as either variants with unknown clinical significance (VUSs) or benign variants based on in silico analyses with limited functional evidence ([@MCS004093TOHC12]; [@MCS004093TOHC15]; [@MCS004093TOHC17]; [@MCS004093TOHC14]). The abundance of VUSs should be reevaluated to facilitate the implementation of epidemiologic studies. Functional studies aimed at evaluating VUSs should assess the various domains*,* such as those of DNA damage repair and apoptosis. Using clinical germline variants, we sought to demonstrate a systematic method of functionally evaluating *BARD1* VUSs.

RESULTS {#s2}
=======

Clinical Presentation and Family History {#s2a}
----------------------------------------

We identified six cases of *BARD1* germline variants (pathogenic variants and VUSs). Three cases were found in patients with breast cancers, whereas the remaining three were in colorectal cancers ([Table 1](#MCS004093TOHTB1){ref-type="table"}). Of the three patients with breast cancer, patient S531 was diagnosed with the aggressive TNBC phenotype at age 34 and has a strong family history of cancer, including a daughter diagnosed with breast cancer at age 28 ([Fig. 1](#MCS004093TOHF1){ref-type="fig"}C). This patient was previously identified to carry a frameshift *BARD1* variant c.2099delG, which results in the loss of the apoptotic domains. Interestingly, all three patients with colorectal cancers presented with colorectal cancers before the age of 50. Patient S490 presented at age 24 with stage IIIB disease and passed away a few years later, whereas patient S493 was diagnosed with stage IVA disease at age 41. Similarly, patient L75 presented with early-onset colorectal cancer with distant metastasis ([Table 1](#MCS004093TOHTB1){ref-type="table"}). All three patients had missense VUSs, located in the apoptotic domains (c.1217G\>A, c.1918C\>A). No pathogenic variants were detected in the breast cancer (for S531) and colorectal cancer susceptibility genes (for L75, S490 and S493) ([Supplemental Materials](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004093/-/DC1)). Last, patient S69 was diagnosed with unilateral ER^+^/PR^+^/HER2^−^ stage IIIA breast cancer with neither recurrence nor family history of cancers ([Fig. 1](#MCS004093TOHF1){ref-type="fig"}A). She carried a missense variant in the nonfunctional region upstream of the RING domain ([Fig. 1](#MCS004093TOHF1){ref-type="fig"}D).

![(*A*--*C*) Pedigrees of the cases identified with *BARD1* germline mutation: (*A*) S69 *BARD1* c.73G\>C, (*B*) S519 *BARD1* c.1833dupT, and (*C*) S531 *BARD1* c.2099delG. (BC) Breast cancer, (CO) colon cancer, (ESO) esophageal cancer, (PanC) pancreatic cancer, (PC) prostate cancer. (*D*) Distribution of *BARD1* germline mutation. Functional domains include the following: RING (residues 26--119), RAD51-binding (residues 123--162), ANK (residues 425--555), and BRCT (residues 566--777). The lolliplots were drawn using St. Jude PeCan Data Portal.](MCS004093Toh_F1){#MCS004093TOHF1}

###### 

Clinicopathological characteristics of the cases identified with *BARD1* germline mutations

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variant                                 Minor allele frequency   Patient demographics   Primary cancer (age at diagnosis)   Stage   Histological features      Other cancers (age at diagnosis)      Other variants   Cancer in first-degree relative (age at diagnosis)
  --------------------------------------- ------------------------ ---------------------- ----------------------------------- ------- -------------------------- ------------------------------------- ---------------- -----------------------------------------------------------------
  S69 *BARD1* c.73G\>C p.Ala25Pro         None                     Chinese female         Right breast cancer (41 yr)         IIIA    IDC grade 3\               None                                  None             None
                                                                                                                                      ER^+^/PR^+^/HER2^−^                                                               

  S519 *BARD1* c.1833dupT p.Asp612Terfs   None                     Chinese female         Right breast cancer (51 yr)         IIB     DCIS high grade\           Contralateral breast cancer (58 yr)   None             Father: esophageal cancer (62 yr)\
                                                                                                                                      ER^+^/PR^−^/HER2 unknown                                                          Mother: colon cancer (72 yr)

  S531 *BARD1* c.2099delG p.Gly700Alafs   None                     Mexican female         Left breast cancer (34 yr)          IIA     Medullary carcinoma\       Contralateral breast cancer (36 yr)   None             Father: prostate cancer (60 yr)\
                                                                                                                                      ER^−^/PR^−^/HER2^−^                                                               Mother: ovarian cancer (52 yr) and pancreatic cancer (unknown)\
                                                                                                                                                                                                                        Brother: prostate cancer (45 yr)\
                                                                                                                                                                                                                        Daughter: breast cancer (28 yr)

  L75 *BARD1* c.1217G\>A p.Arg406Gln      0.00004124               Chinese female         Descending colon cancer (37 yr)     IVB     Adenocarcinoma grade 2     None                                  None             None

  S490 *BARD1* c.1217G\>A p.Arg406Gln     0.00004124               Chinese female         Transverse colon cancer (24 yr)     IIIB    Adenocarcinoma grade 2     None                                  None             None

  S493 *BARD1* c.1918C\>A p.Leu640Ile     None                     Malay male             Rectal cancer (41 yr)               IVA     Adenocarcinoma grade 2     None                                  None             None
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To establish the presence of clinical and tumor phenotype of *BARD1* germline variants, we referred to the Cancer Genome Atlas (TCGA) data set. Given that the majority of *BARD1* germline variants were reported among breast cancer patients, we examined the TCGA breast cancer subset for presence of *BARD1* germline variants. Of the 1036 breast cancer patients, only 33 patients carried *BARD1* germline variants ([Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004093/-/DC1)). Of these, only two patients had pathogenic variants (c.729T\>A, c.1690C\>T). The remaining patients carried benign variants (c.1972C\>T, c.2212A\>G) and VUSs (c.581G\>A, c.620A\>G, c.1016G\>A, c.1738G\>A, c.2191C\>G, c.2282G\>A) ([Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004093/-/DC1)). Both patients with the truncating pathogenic variants (c.729T\>A, c.1690C\>T) had infiltrating duct carcinoma, similar to the majority of the breast cancer patients.

We proceeded to investigate for a distinct mutational spectrum among tumors associated with *BARD1* germline variants, based on the initial findings of a case report; [@MCS004093TOHC28] found several features of BRCA-ness in a non-BCRA-related breast cancer containing heterozygous *BARD1* germline variants with tumor loss of heterozygosity. Using the TCGA BRCA data set, we did not find any unique mutational spectrum among tumors associated with *BARD1* germline variants ([Supplemental Fig. S4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004093/-/DC1)). None of the tumors carried signature 3, which was associated with *BRCA1* and *BRCA2* variants ([@MCS004093TOHC25]).

Genomic Analyses {#s2b}
----------------

Overall, there were five unique germline variants in the six patients ([Table 2](#MCS004093TOHTB2){ref-type="table"}); one VUS, *BARD1* c.1217G\>A, was seen in both patient S490 with stage IIIB colorectal cancer and patient L75 with metastatic colorectal cancer. Of all the variants, only *BARD1* c.1217G\>A was reported in the literature ([@MCS004093TOHC29]). Two were pathogenic/likely pathogenic frameshift variants (*BARD1* c.1833dupT and *BARD1* c.2099delG), and the remaining three were missense VUSs (*BARD1* c.73G\>C, *BARD1* c.1217G\>A, *BARD1* c.1918C\>A). The majority of these germline variants involved the ANK and BRCT domains ([Fig. 1](#MCS004093TOHF1){ref-type="fig"}D). Only one, *BARD1* c.73G\>C, was located at the 5′ terminus proximal to the RING domain. Both pathogenic/likely pathogenic variants were located in the BRCT domain, consistent with the distribution of germline pathogenic variants reported in the literature ([Fig. 1](#MCS004093TOHF1){ref-type="fig"}; [Supplemental Materials](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004093/-/DC1)).

###### 

Variant table

  Gene      Variant                    Chromosome   HGVS DNA reference   HGVS protein reference   Variant type   Predicted effect (substitution, deletion, etc.)   dbSNP/dbVar ID   Allele registry ID   ClinVar variation ID   Genotype (heterozygous/homozygous)
  --------- -------------------------- ------------ -------------------- ------------------------ -------------- ------------------------------------------------- ---------------- -------------------- ---------------------- ------------------------------------
  *BARD1*   c.73G\>C p.Ala25Pro        2            NM_000465            NP_000456                Missense       Substitution                                      rL751646468      CA333878             185,506                Heterozygous
  *BARD1*   c.1833dupT p.Asp612Terfs   2            NM_000465            NP_000456                Nonsense       Duplication                                       rs1553614963     CA658796163          530,030                Heterozygous
  *BARD1*   c.2099delG p.Gly700Alafs   2            NM_000465            NP_000456                Nonsense       Deletion                                          rs1553612184     CA658796159          530,114                Heterozygous
  *BARD1*   c.1217G\>A p.Arg406Gln     2            NM_000465            NP_000456                Missense       Substitution                                      rs587780014      CA287510             127,713                Heterozygous
  *BARD1*   c.1918C\>A p.Leu640Ile     2            NM_000465            NP_000456                Missense       Substitution                                      rs1553612535     CA350451296          530,056                Heterozygous
  *BARD1*   c.1670G\>C p.Cys557Ser     2            NM_000465            NP_000456                Missense       Substitution                                      rs28997576       CA250552             8045                   Heterozygous

Functional Analyses {#s2c}
-------------------

We evaluated each variant for the functions encoded by the various domains: RING domain for BARD1--BRCA1 colocalization, RAD51-binding domain for foci formation, and the ANK, BRCT domains for apoptosis. To induce double-stranded DNA breaks and subsequently apoptosis, cells were treated with etoposide. Colocalization of BARD1 and BRCA1 foci was observed at 24 h post--etoposide treatment ([Fig. 2](#MCS004093TOHF2){ref-type="fig"}A). For the RAD51 foci assays, double-stranded DNA breaks were induced from the etoposide treatment, as evident from the rise in ɣ-H2AX foci ([Fig. 2](#MCS004093TOHF2){ref-type="fig"}C). This was accompanied with a rise in RAD51 foci as homologous recombination repair was initiated ([Fig. 2](#MCS004093TOHF2){ref-type="fig"}C,D). All the variants displayed normal BARD1--BRCA1 colocalization and RAD51 foci formation, consistent with the absence of mutations at the RING and RAD51-binding domains, respectively ([Fig. 1](#MCS004093TOHF1){ref-type="fig"}D).

![(*A*) BARD1--BRCA1 colocalization was observed for all the *BARD1* variants. BARD1 and BRCA1 foci were stained green and red, respectively. (*B*) Basal levels of BARD1 expression were lower in *BARD1* c.1833dupT and *BARD1* c.2099delG as compared to healthy controls. (*C*,*D*) RAD51 foci (green) were colocalized at the sites of DNA breaks as represented by ɣ-H2AX foci (red). Scale bar, 10 µm. No statistically significant difference in RAD51 localization was noted between the *BARD1* variants and the healthy controls. An independent *t*-test was used to compare the results between the variants and healthy controls.](MCS004093Toh_F2){#MCS004093TOHF2}

To investigate the variants' impact on apoptosis, we measured the extent of DNA fragmentation and membrane phosphatidylserine translocation via TUNEL and Annexin V assays, respectively. Compared to the healthy controls, all the VUSs, except *BARD1* c.73G\>C, displayed a lower extent of apoptosis ([Fig. 3](#MCS004093TOHF3){ref-type="fig"}A,B). This observed trend was consistent with the mutation sites of the VUSs in which all but *BARD1* c.73G\>C involved the ANK and BRCT domains. In addition, *BARD1* c.1833dupT and *BARD1* c.2099delG showed a greater extent of impaired apoptosis ([Fig. 3](#MCS004093TOHF3){ref-type="fig"}A). Interestingly, patients with these variants also showed reduced BARD1 expression ([Fig. 2](#MCS004093TOHF2){ref-type="fig"}B). To determine whether the reduced expression was the cause of the impaired apoptosis would require further studies. In view of the above findings, *BARD1* c.1918C\>A and *BARD1* c.1217G\>A might be pathogenic, whereas *BARD1* c.73G\>C is likely a benign variant ([Table 3](#MCS004093TOHTB3){ref-type="table"}).

![(*A*) TUNEL and (*B*) Annexin V assays. Percentage rise in apoptosis for the variants was normalized to that of the healthy controls. When compared to the healthy control, posttreatment apoptosis was lower for all the *BARD1* variants, except *BARD1* c.73G\>C. (\*) *P* \< 0.05, (\*\*) *P* \< 0.005. Cells containing *TP53* c.817C\>T were included as positive control of impaired apoptosis. An independent *t*-test was used to compare the results between the variants and healthy controls.](MCS004093Toh_F3){#MCS004093TOHF3}

###### 

Compiled in silico prediction and functional results of the variants

  Variant                                 In silico prediction^a^   BARD1--BRCA1 colocalization^b^   RAD51 foci formation^b^   TUNEL assay^c^     Annexin V assay   Overall functional status
  --------------------------------------- ------------------------- -------------------------------- ------------------------- ------------------ ----------------- -----------------------------
  S69 *BARD1* c.73G\>C p.Ala25Pro         Likely tolerated          Normal                           Normal                    Normal             Normal            Intact
  L75 *BARD1* c.1217G\>A p.Arg406Gln      Likely tolerated          Normal                           Normal                    Impaired (0.8)     Impaired (0.7)    Possibly impaired apoptosis
  S490 *BARD1* c.1217G\>A p.Arg406Gln     Likely tolerated          Normal                           Normal                    Impaired (0.8)     Impaired (0.4)    Possibly impaired apoptosis
  S493 *BARD1* c.1918C\>A p.Leu640Ile     Conflicting               Normal                           Normal                    Impaired (0.7)     Impaired (0.5)    Possibly impaired apoptosis
  S519 *BARD1* c.1833dupT p.Asp612Terfs   Not applicable            Normal                           Normal                    Impaired (\<0.2)   Impaired (0.4)    Impaired apoptosis
  S531 *BARD1* c.2099delG p.Gly700Alafs   Not applicable            Normal                           Normal                    Impaired (\<0.2)   Impaired (0.7)    Impaired apoptosis

^a^In silico prediction results were based on PolyPhen-2, Align GVD, and SIFT prediction tools.

^b^Function was considered as intact if not statistically different from healthy controls.

^c^Rise in apoptosis for variants was normalized to that of healthy controls, in parentheses. Values were rounded to the nearest decimal.

DISCUSSION {#s3}
==========

Determining the pathogencity of a germline variant is critical for the management of patients and their families, and depends largely on both epidemiologic and functional evidence. Given the rarity of *BARD1* germline variants, epidemiologic studies that require large samples of carriers may not be feasible ([@MCS004093TOHC21]). Hence, functional studies are crucial to the curation of *BARD1* germline variants. Despite BARD1\'s indispensable role as the binding partner of BRCA1*,* most *BARD1* VUSs (90%) and all of the *BARD1* germline pathogenic variants have never been functionally assessed ([@MCS004093TOHC20]). Here, we performed functional characterization of two pathogenic/likely pathogenic variants and three VUSs. The impaired apoptosis associated with variants c.1217G\>A and c.1918C\>A may provide evidence toward a likely pathogenic or pathogenic classification. However, there remains insufficient evidence for variant reclassification according to American College of Clinical Genetics (ACMG) criteria ([@MCS004093TOHC27]). Additional evidence, such as epidemiologic research, is still required.

Clinically, carriers of these pathogenic/likely pathogenic variants displayed several features suggestive of a more aggressive tumor phenotype, such as having early metastatic diseases, multiple tumors, and frequent tumor recurrence. Other studies have also suggested distinct and aggressive tumor phenotypes (i.e., TNBCs) associated with *BARD1* germline pathogenic variants; empirically, a patient with a nonsense germline variant (c.1921C\>T) was found to have multiple bilateral breast cancers ([@MCS004093TOHC2]; [@MCS004093TOHC28]; [@MCS004093TOHC23]; [@MCS004093TOHC5]; [@MCS004093TOHC4]; [@MCS004093TOHC11]). However, with *BARD1* being a low-penetrance gene, these phenotypes are unlikely caused solely by the respective *BARD1* pathogenic variants ([@MCS004093TOHC7]). Low- to moderate-penetrance genes have been demonstrated in model-fitting studies, to act multiplicatively in raising cancer risk ([@MCS004093TOHC32]). Studies on larger cohorts of patients with pathogenic *BARD1* variants will be needed to further elucidate these clinicopathological characteristics and any potential modifying factors that may explain the variable cancer risks observed in previous *BARD1* studies ([@MCS004093TOHC17], [@MCS004093TOHC18]; [@MCS004093TOHC16]; [@MCS004093TOHC6]; [@MCS004093TOHC26]; [@MCS004093TOHC19]).

More importantly, we showed that the type of aberrant protein function correlated with the domain location of the variant. Variants that displayed impaired apoptosis (c.1918C\>A, c.1833dupT, c.1217G\>A, and c.2099delG) were located within and proximal to the apoptotic domains of ankyrin and BRCT. On the other hand, none of these variants displayed abnormal BRCA1 heterodimerization or RAD51 colocalization given that they were located distal to the BRCA1- and RAD51-binding domains. Therefore, it is important to use the appropriate functional assay relevant to the site of mutation.

Assessing BARD1 functional status will require a composite of different assays. A recent functional analysis of 29 *BARD1* missense variants evaluated for functional impairment using the homology-directed DNA repair (HDR) assay ([@MCS004093TOHC21]). The HDR assay measures the signal of green fluorescent protein in mutant cells containing double-stranded DNA breaks from the expression of endonuclease I-SceI. For many homologous recombination genes such as *BRCA2*, the HDR assay serves as a relatively high-throughput method of analyzing VUSs ([@MCS004093TOHC9]). In this study, 13 of the 29 *BARD1* variants evaluated in the functional analysis were located in the ANK and BRCT domains and showed an intact homologous recombination function ([@MCS004093TOHC21]). The use of the Annexin V assay or other apoptotic assays might have provided further evidence of their functional impact. Similarly, in another study on *BARD1* germline variants, two variants were found to be functionally intact using the apoptotic assays ([@MCS004093TOHC29]). Given that these variants were located in the BRCA1- and RAD51-binding domains ([@MCS004093TOHC29]), the addition of the HDR assay would have complemented the apoptosis findings.

The two *BARD1* pathogenic variants included in our study, c.1833dupT and c.2099delG, were located within the BRCT domains. Unsurprisingly, they displayed impaired apoptosis but normal DNA damage repair. An indiscriminate use of the DNA damage repair assay alone would have otherwise missed the impaired apoptosis of these clinically pathogenic variants and would have misguided variant classification. Another of our variants, *BARD1* c.1217C\>A, was previously classified as benign based on its preserved homologous recombination function. Although we also observed intact DNA damage repair from our RAD51 assay, our additional apoptosis studies revealed impaired apoptosis in this variant (∼20%--60% lower than healthy controls). This may be because of the proximity of the variant to the ANK domain; structural analysis of the mutant protein would be useful to reevaluate the functional status of this variant.

In summary, we illustrated a systematic way of evaluating VUSs located in the DNA repair, apoptosis, and BRCA1-binding domains. However, a potential limitation of our assays involved the exclusion of more recent gene functions such as the repair of stalled replication forks and transcriptional regulation of estrogen metabolizing genes that are located in the BRCA1-binding and BRCT domains, respectively ([@MCS004093TOHC3]; [@MCS004093TOHC30]). Ideally, functional assays should incorporate all the newly discovered gene functions. This may not be feasible as functional studies are costly and time-consuming. Nonetheless, reliable functional evidence can be efficiently obtained with the use of the appropriate assay, as emphasized in our study. Moreover, our choice of functional assays already covered both the BRCA1-binding and BRCT domains.

Ultimately, the overall evidence for variant classification pivots on the genetic and epidemiologic analyses ([@MCS004093TOHC22]). Large cohort studies on *BARD1* pathogenic variants are still needed to assess the clinical relevance of this gene, as well as to elucidate potential genetic risk modifiers causing the observed variability of penetrance between and within families. To facilitate this, functional evaluation of the VUSs should be focused and specific to the variant\'s location.

METHODS {#s4}
=======

This study was approved by the SingHealth Centralized Institutional Review Board (IRB 2010/426/B) with signed informed consent from the participants.

Study Design {#s4a}
------------

Patients referred to the Cancer Genetics Service at the National Cancer Centre Singapore between November 2014 and March 2018 were reviewed retrospectively for *BARD1* germline pathogenic variants and VUSs. These variants were curated by a clinical laboratory accredited by the College of American Pathologists and Clinical Laboratory Improvement Amendments, in accordance with the criteria by the ACMG. Variant c.1918C\>A was curated separately by us with reference to the ACMG guidelines as the carrier was not tested by clinical laboratories ([Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004093/-/DC1)). Only patients who had provided research consent and those with previously banked lymphoblastoid cells were included. Clinicopathological data for age, sex, personal and cancers in first-degree relatives, tumor histology, American Joint Committee on Cancer (AJCC) staging, site, and immunohistochemistry (IHC) staining of estrogen, progesterone, and erbB-2 receptors were retrieved from electronic medical records. Pedigrees for each patient were constructed and drawn using Progeny Pedigree Drawing Software (Progeny Software LLC). To compare the overall distribution of *BARD1* germline variants with that observed in our study, we performed a literature search using ClinVar.

Cell Culture and Treatment {#s4b}
--------------------------

Patient-derived lymphoblastoid cells were treated with 10 µM etoposide for 1 h to induce double-stranded DNA breaks, subsequently recovered by incubation in fresh medium. Vehicle control containing an equivalent volume of DMSO was used. Recovery durations of 12 h and 24 h were used for the assay on RAD51 foci formation and BARD1--BRCA1 colocalization, respectively. Cells were then harvested for immunofluorescence studies.

Immunofluorescence (IF) Studies of BARD1--BRCA1 Colocalization and RAD51 Foci Formation {#s4c}
---------------------------------------------------------------------------------------

Cells were fixed for 15 min using 4% paraformaldehyde, were permeabilized for 5 min using 0.3% Triton-X 100, and were blocked for 30 min with 10% goat serum in phosphate-buffered saline before incubation for 30 min at 37°C with primary antibodies. Slides were then stained with secondary antibodies for 1 h at room temperature before being mounted with Prolong Gold antifade reagent with DAPI (Life Technologies, ThermoFisher Scientific Corporation). The images were acquired by confocal microscope (Zeiss LSM800). Cells containing five or more foci were scored positive for RAD51 foci formation. At least 200 cells were counted for each slide, and duplicates were performed for each experiment.

Western Blot Analysis of BARD1 Basal Expression {#s4d}
-----------------------------------------------

Cell pellets were lysed in RIPA buffer supplemented with protease and phosphatase inhibitor cocktail (ThermoFisher Scientific Corporation), and protein extracts were quantified using the Pierce BCA protein assay kit (ThermoFisher Scientific Corporation). Proteins were then electrophoresed on sodium dodecyl sulfate polyacrylamide gel and transferred to polyvinylidene difluoride membrane (Milipore, Sigma-Aldrich). Membranes were blocked, and then incubated overnight with primary antibody followed by secondary antibodies. Immunoreactivity was detected with enhanced chemiluminescent HRP substrate (Advansta).

Apoptosis Studies {#s4e}
-----------------

### TUNEL assay {#s4e1}

Cells were pretreated with 10 µM etoposide or DMSO in 5% RPMI for 24 h. Subsequently, cell apoptosis was measured with a microplate reader--based TiterTACS in situ apoptosis detection kit (R&D systems; 4822-96-K) as described by the manufacturer. Percentage rise in apoptosis was derived from the difference in absorbance between the etoposide-treated and DMSO-treated wells. Minimum of duplicates were performed for each experiment.

### Annexin V assay {#s4e2}

Cells were pretreated with 10 µM etoposide or DMSO in 5% RPMI for 6 h before incubation in fresh medium for up to 24 h. Subsequently, the cells were harvested and stained with Annexin V and propidium iodide according to manufacturer\'s protocol (BD Biosciences; 556547). Cells in early apoptosis are Annexin V positive and PI negative, whereas cells in late apoptosis or necrosis are both Annexin V and PI positive. For our study, we only considered apoptotic cells with Annexin V positive and PI negative. Cells with double staining were excluded, given that some of these cells might have died via necrosis. A minimum of triplicates was performed for each experiment.
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======================

Data Deposition and Access {#s5a}
--------------------------

The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request. The variants have been deposited in ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) and can be found under accession numbers SCV000920886, SCV000920887, SCV000920888, SCV000920889, and SCV000920890.
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